Clinical trials: Central Nervous System (CNS) Metastases
Recurrent Medulloblastoma, Refractory Medulloblastoma
A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)
The purpose of this study is to find out whether 177Lu-DPTA-omburtamab is a safe treatment for children and adolescents with recurrent/refractory medulloblastoma or another type of cancer with CNS metastases.
- Conditions
- Recurrent Medulloblastoma, Refractory Medulloblastoma, CNS Metastases, Central Nervous System Metastasis
- Trial name
- NCT07698899
- Testing
- 25 mCi 177Lu- DTPA-omburtamab
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases
Material Balance of [14C]Zorifertinib in Healthy Adult Male Participants in China
This is a single-center, single-dose, open-label, Phase I study to evaluate the mass balance, biotransformation, pharmacokinetic characteristics, excretion pathways, and safety of a single oral 200 mg/5 µCi dose of…
- Trial name
- NCT07620951
- Testing
- [14C]Zorifertinib Oral Formulation
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Alpha Biopharma (Jiangsu) Co., Ltd.
Central Nervous System (CNS) Metastases, Breast Cancer
A Phase II Observational Clinical Study on the Relationship Between Cerebrospinal Fluid Drug Concentration and Efficacy of Trastuzumab Deruxtecan in Central Nervous System Metastatic Breast Cancer
Approximately 5-15% breast cancer patients develop brain metastases. Current local treatments (surgery/radiotherapy) are associated with significant complications, and systemic treatments have limited efficacy.
- Trial name
- BCBM006 (NCT07653893)
- Testing
- No Interventions
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
This study is a patient-centered, two-group, three-cohort, multi-center, prospective study to further evaluate the survival benefits and safety of zorifertinib as a first-line treatment in EGFRm+ advanced NSCLC patients with CNS…
- Trial name
- NCT07143045
- Testing
- zorifertinib
- Where
- 34 sites in China
- Volunteers
- 800 people
- Sponsor
- Alpha Biopharma (Jiangsu) Co., Ltd.
Central Nervous System (CNS) Lesions, Brain Metastases
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain tumors or multiple sclerosis.
- Conditions
- Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms, Brain Neoplasms, Benign
- Trial name
- NCT06322342
- Testing
- RVP-001
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Reveal Pharmaceuticals Inc.
Brain Metastases, CNS Neoplasm
HyperArc Registry Study
The HyperArc registry is designed to collect data from which the efficacy of the HyperArc procedure can be assessed and compared to alternative treatments.
- Conditions
- Brain Metastases, CNS Neoplasm, CNS Disorder, Intracranial
- Trial name
- NCT05270707
- Testing
- Stereotactic radiosurgery
- Where
- 7 sites in United States, Australia and 2 more
- Volunteers
- 968 people
- Sponsor
- Varian, a Siemens Healthineers Company
Breast Cancer, Brain Metastases
TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases
This is a single arm, open label trial to assess the safety and efficacy of tucatinib in combination with pembrolizumab and trastuzumab for the treatment of HER2+ breast cancer brain metastases (BCBM).
- Conditions
- Breast Cancer, Brain Metastases, HER2-positive Breast Cancer, CNS Disease
- Trial name
- TOPAZ (NCT04512261)
- Testing
- Tucatinib, Pembrolizumab, Trastuzumab
- Where
- United States
- Sponsor
- Reva Basho
Metastatic Breast Cancer, Central Nervous System (CNS) Metastases
Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases
The purpose of this study is to see if capecitabine can be taken safely with different doses of lapatinib in patients with HER-2 positive breast cancer involving brain (brain metastases) and/or in spinal fluid (leptomeningeal…
- Trial name
- NCT02650752
- Testing
- Lapatinib in Tandem With Capecitabine
- Where
- 9 sites in United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Central Nervous System (CNS) Metastases, Brain Metastases
Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors
The specific purpose of this study is to obtain data on safety and efficacy of combination chemotherapy with Temozolomide and Topotecan in patients with CNS metastases of solid tumors.
- Trial name
- NCT01736800
- Testing
- Topotecan, Temozolomide
- Where
- 2 sites in United States
- Sponsor
- The Methodist Hospital Research Institute